The heparin anti-Xa therapeutic range: Are we there yet? [3] (multiple letters)

Chest

Volumn 121, Issue 1, 2002, Pages 303-304

  Smythe, Maureen A ^a   Mattson, Joan C ^a   Koerber, Jhon M ^a   Hull, Russell D ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A ANTIBODY; CHROMOGENIC SUBSTRATE; HEPARIN; NEUTRALIZING ANTIBODY; PROTAMINE SULFATE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNOASSAY; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOEMBOLISM; TITRIMETRY; VEIN THROMBOSIS;

EID: 0036158044     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.1.303     Document Type: Letter

References (14)

1. Sixth ACCP Consensus Conference on Antithrombotic Therapy Chest 119 suppl 2001 1S 370S
2. G Guyatt H Schunemann D Cook Grades of recommendation for antithrombotic agents Chest 2001 3S 7S
3. Fifth ACCP Consensus Conference on Antithrombotic Therapy Chest 114 suppl 1998 1S 769S
4. TM Hyers G Agnelli RD Hull Antithrombotic therapy for venous thromboembolic disease Chest 114 suppl 1998 561S 578S
5. J Hirsh TE Warkentin R Raschke Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety Chest 114 suppl 1998 489S 510S
6. TM Hyers G Agnelli RD Hull Antithrombotic therapy for venous thromboembolic disease Chest 119 suppl 2001 176S 193S
7. MA Smythe JK Koerber Heparin monitoring: the confusion continues Pharmacotherapy 19 1999 1240 1242
8. MN Levine J Hirsh M Gent A randomized trial comparing activated partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin Arch Intern Med 154 1994 49 56
9. S Kitchen FE Preston The therapeutic range of heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays Thromb Haemost 75 1996 734 739
10. CT Taylor WP Petros TL Ortel Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring Pharmacotherapy 19 1999 383 387
11. BA Baker MS Adelman OA Smith Inability of the activated partial thromboplastin time to predict heparin levels Arch Intern Med 157 1997 2475 2479
12. S Kitchen J Theaker FE Preston Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay Blood Coagul Fibrinolysis 11 2000 137 144
13. MJ Kovacs M Keeney K Mackinnon Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin Clin Lab Haematol 21 1999 55 60
14. JD Olson CF Arkin JT Brandt College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy, laboratory monitoring of unfractionated heparin therapy Arch Pathol Lab Med 122 1998 782 798